Kareem Abu-Elmagd, MD, PhD

216.445.8876

Kareem Abu-Elmagd, MD, PhD

Appointed: 2012

Kareem Abu-Elmagd, MD, PhD
Department: Transplantation Center
Director
Location: Cleveland Clinic Main Campus
Mail Code A100
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.445.8876
WorkFax:216.636.5604
Kareem Abu-Elmagd, MD, PhD
Department: Hepato-pancreato-biliary and Transplant Surgery
Location: Cleveland Clinic Main Campus
Mail Code A100
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.445.8876
WorkFax:216.636.5604
Kareem Abu-Elmagd, MD, PhD
Department: General Surgery Florida
Location: Florida, Weston
Mail Code A100
2950 Cleveland Clinic Boulevard
Weston, FL 33331
WorkAppointment:216.445.8876
WorkFax:216.636.5604
Surgeon:
Yes
Treats:
Both Adults and Children & Adolescents

Biographical Sketch

Kareem Abu-Elmagd, MD, PhD,has joined the Department of General Surgery in the Digestive Disease Institute as Director of the Intestinal Transplant Program. During the next few months, Dr. Abu-Elmagd will take on leadership of the Transplant Center from John Fung, MD, Chairman of the Digestive Disease Institute, who has directed the center until now. Dr. Abu-Elmagd has led the Intestinal Rehabilitation and Transplant Center at the University of Pittsburgh (UPMC) since its establishment in 1999 and has earned an international reputation for clinical and technical contributions to the field of transplantation. He has authored more than 300 original publications and 40 book chapters. He is an active member of 13 prominent professional and scientific societies.

In 1999, Dr. Abu-Elmagd convinced the Center for Medicare and Medicaid Services (CMS) that, due to improved survival rates, intestinal and multivisceral transplantation programs should receive reimbursement.

In addition to his clinical and surgical expertise in the field of liver transplantation, Dr. Abu-Elmagd has also made significant global contributions to the field of portal hypertensive surgery. He played a pivotal role in the development and introduction of the immunosuppressive drug FK506, also known as Prograf.

Professional Highlights

President, Intestinal Transplant Association

Education & Fellowships

Residency - University of Pittsburgh Medical Center
General Surgery
Pittsburgh, PA
1997
Fellowship - University of Pittsburgh Medical Center
Transplantation
Pittsburgh, PA
1990
Doctorate - Emory University School of Medicine
Atlanta, GA USA
1987
Doctorate - Mansoura University School of Medicine
Mansoura Egypt
1987
Research Fellowship - Emory University School of Medicine
Surgery
Atlanta, GA USA
1986
Research Fellowship - Wayne State University
Pathology
Detroit, MI USA
1983
Residency - Mansoura University Hospital
Surgical Resident
Mansoura Egypt
1982
Graduate - Mansoura University School of Medicine
Mansoura Egypt
1981
Residency - Hurghada General Hospital
Surgical Resident
Hurghada Egypt
1979
Medical School - Mansoura University School of Medicine
Mansoura Egypt
1976

Certifications

  • Surgery

Memberships

  • American Association for the Study of Liver Diseases
  • The International Liver Transplantation Society
  • The American Medical Association
  • The American Society of Transplant Surgeons
  • The American Society of Transplantation
  • The Transplantation Society
  • The American Surgical Society
  • The American Surgical Association

Treatment & Services

  • Intestinal Rehabilitation & Transplant
  • Intestinal Transplant
  • Small Bowel Transplant

Specialty in Diseases and Conditions

  • Autoimmune Chronic Hepatitis
  • Portal Hypertension
  • Primary Biliary Cirrhosis
  • Primary Sclerosing Cholangitis

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 1/3/2014, Dr. Abu-Elmagd has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • Arabic
  • English
Cleveland Clinic Mobile Site